157 related articles for article (PubMed ID: 23739952)
21. [Structure and activity of carvedilol].
Zarudyĭ FS; Garifullin BN; Zakirova AN
Eksp Klin Farmakol; 2010 Jan; 73(1):40-3. PubMed ID: 20184288
[TBL] [Abstract][Full Text] [Related]
22. Estimation of carvedilol in human plasma by using HPLC-fluorescence detector and its application to pharmacokinetic study.
Rathod R; Prasad LP; Rani S; Nivsarkar M; Padh H
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 857(2):219-23. PubMed ID: 17702675
[TBL] [Abstract][Full Text] [Related]
23. Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction.
Sica DA
Am J Cardiol; 2006 Oct; 98(7A):1L-4L. PubMed ID: 17023226
[No Abstract] [Full Text] [Related]
24. Novel design and synthesis of modified structure of carvedilol.
Hashemzadeh M; Movahed MR; Russu WA; Soroush L; Hill DN
Recent Pat Cardiovasc Drug Discov; 2011 Sep; 6(3):175-9. PubMed ID: 21834769
[TBL] [Abstract][Full Text] [Related]
25. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction.
Neugebauer G; Gabor M; Reiff K
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S142-6. PubMed ID: 1378143
[TBL] [Abstract][Full Text] [Related]
26. Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues.
Stahl E; Mutschler E; Baumgartner U; Spahn-Langguth H
Arch Pharm (Weinheim); 1993 Sep; 326(9):529-33. PubMed ID: 7902078
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
Hsiao HL; Langenickel TH; Greeley M; Roberts J; Zhou W; Pal P; Rebello S; Rajman I; Sunkara G
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):407-17. PubMed ID: 27137712
[TBL] [Abstract][Full Text] [Related]
28. Design and in vivo evaluation of carvedilol buccal mucoadhesive patches.
Thimmasetty J; Pandey G; Babu P
Pak J Pharm Sci; 2008 Jul; 21(3):241-8. PubMed ID: 18614419
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
[TBL] [Abstract][Full Text] [Related]
30. Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach.
Rasool MF; Khalil F; Läer S
Drug Metab Dispos; 2016 Jul; 44(7):1103-15. PubMed ID: 27068272
[TBL] [Abstract][Full Text] [Related]
31. Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats.
Lim TH; Cho YA; Choi DH
J Physiol Pharmacol; 2015 Aug; 66(4):591-7. PubMed ID: 26348083
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic properties of a new controlled-release formulation of carvedilol.
Tenero DM; Henderson LS; Baidoo CA; Harter AH; Campanile AM; Danoff TM; Boyle D
Am J Cardiol; 2006 Oct; 98(7A):5L-16L. PubMed ID: 17023227
[TBL] [Abstract][Full Text] [Related]
33. UGT2B7*3 did not affect the pharmacokinetics of R- and S-carvedilol in healthy Japanese.
Honda M; Toyoda W; Shimizu T; Horiuchi I; Kayano Y; Taguchi M; Nozawa T; Inoue H; Hashimoto Y
Drug Metab Pharmacokinet; 2007 Oct; 22(5):382-6. PubMed ID: 17965522
[TBL] [Abstract][Full Text] [Related]
34. Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.
Takekuma Y; Takenaka T; Yamazaki K; Ueno K; Sugawara M
Biol Pharm Bull; 2007 Nov; 30(11):2146-53. PubMed ID: 17978490
[TBL] [Abstract][Full Text] [Related]
35. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
Graff DW; Williamson KM; Pieper JA; Carson SW; Adams KF; Cascio WE; Patterson JH
J Clin Pharmacol; 2001 Jan; 41(1):97-106. PubMed ID: 11225566
[TBL] [Abstract][Full Text] [Related]
36. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
Kim MS; Baek IH
Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006
[TBL] [Abstract][Full Text] [Related]
37. Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol.
Ohno A; Saito Y; Hanioka N; Jinno H; Saeki M; Ando M; Ozawa S; Sawada J
Drug Metab Dispos; 2004 Feb; 32(2):235-9. PubMed ID: 14744946
[TBL] [Abstract][Full Text] [Related]
38. Assay and disposition of carvedilol enantiomers in humans and monkeys: evidence of stereoselective presystemic metabolism.
Fujimaki M; Murakoshi Y; Hakusui H
J Pharm Sci; 1990 Jul; 79(7):568-72. PubMed ID: 1975840
[TBL] [Abstract][Full Text] [Related]
39. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol.
Stoschitzky K; Stoschitzky G; Brussee H; Bonelli C; Dobnig H
Cardiology; 2006; 106(4):199-206. PubMed ID: 16679760
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Apatinib on the Metabolism of Carvedilol Both in vitro and in vivo.
Lin D; Wang Z; Li J; Wang L; Wang S; Hu GX; Liu X
Pharmacology; 2016; 97(1-2):31-7. PubMed ID: 26569478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
